Parker C - Search Results

1

Best Approaches and Updates for Prostate Cancer Biochemical Recurrence.

Simon NI, Parker C, Hope TA, Paller CJ. Simon NI, et al. Among authors: parker c. Am Soc Clin Oncol Educ Book. 2022 Apr;42:1-8. doi: 10.1200/EDBK_351033. Am Soc Clin Oncol Educ Book. 2022. PMID: 35503984 Free PMC article. Review.

2

The management of PSA failure after radical radiotherapy for localized prostate cancer.

Parker CC, Dearnaley DP. Parker CC, et al. Radiother Oncol. 1998 Nov;49(2):103-10. doi: 10.1016/s0167-8140(98)00107-8. Radiother Oncol. 1998. PMID: 10052875 Review.

3

Pre-treatment nomogram for biochemical control after neoadjuvant androgen deprivation and radical radiotherapy for clinically localised prostate cancer.

Parker CC, Norman AR, Huddart RA, Horwich A, Dearnaley DP. Parker CC, et al. Br J Cancer. 2002 Mar 4;86(5):686-91. doi: 10.1038/sj.bjc.6600160. Br J Cancer. 2002. PMID: 11875726 Free PMC article. Clinical Trial.

4

Radical radiotherapy for prostate cancer.

Parker CC, Dearnaley DP. Parker CC, et al. Cancer Treat Rev. 2003 Jun;29(3):161-9. doi: 10.1016/s0305-7372(03)00070-7. Cancer Treat Rev. 2003. PMID: 12787711 Review.

5

The role of hemoglobin concentration in clinically localized prostate cancer treated with radical radiotherapy +/- neoadjuvant androgen deprivation.

Parker C, Warde P, Norman A, Panzarella T, Catton C, Horwich A, Huddart R, Dearnaley D. Parker C, et al. Int J Radiat Oncol Biol Phys. 2004 Jan 1;58(1):53-8. doi: 10.1016/s0360-3016(03)00821-6. Int J Radiat Oncol Biol Phys. 2004. PMID: 14697420

6

Early outcomes of active surveillance for localized prostate cancer.

Hardie C, Parker C, Norman A, Eeles R, Horwich A, Huddart R, Dearnaley D. Hardie C, et al. Among authors: parker c. BJU Int. 2005 May;95(7):956-60. doi: 10.1111/j.1464-410X.2005.05446.x. BJU Int. 2005. PMID: 15839912

7

The utility of digital rectal examination after radical radiotherapy for prostate cancer.

Doneux A, Parker CC, Norman A, Eeles R, Howich A, Huddart R, Dearnaley D. Doneux A, et al. Among authors: parker cc. Clin Oncol (R Coll Radiol). 2005 May;17(3):172-3. doi: 10.1016/j.clon.2004.10.009. Clin Oncol (R Coll Radiol). 2005. PMID: 15901001

8

Docetaxel for the treatment of prostate cancer.

Gilbert DC, Parker C. Gilbert DC, et al. Among authors: parker c. Future Oncol. 2005 Jun;1(3):307-14. doi: 10.1517/14796694.1.3.307. Future Oncol. 2005. PMID: 16556003 Review.

9

Predictors of histological disease progression in untreated, localized prostate cancer.

Venkitaraman R, Norman A, Woode-Amissah R, Fisher C, Dearnaley D, Horwich A, Huddart R, Khoo V, Thompson A, Parker C. Venkitaraman R, et al. Among authors: parker c. J Urol. 2007 Sep;178(3 Pt 1):833-7. doi: 10.1016/j.juro.2007.05.038. Epub 2007 Jul 16. J Urol. 2007. PMID: 17631355

10

Phase I clinical trial of a selective inhibitor of CYP17, abiraterone acetate, confirms that castration-resistant prostate cancer commonly remains hormone driven.

Attard G, Reid AH, Yap TA, Raynaud F, Dowsett M, Settatree S, Barrett M, Parker C, Martins V, Folkerd E, Clark J, Cooper CS, Kaye SB, Dearnaley D, Lee G, de Bono JS. Attard G, et al. Among authors: parker c. J Clin Oncol. 2008 Oct 1;26(28):4563-71. doi: 10.1200/JCO.2007.15.9749. Epub 2008 Jul 21. J Clin Oncol. 2008. PMID: 18645193 Clinical Trial.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

3,100 results

Search Page